Skip to main content

Improved anthrax vaccine

A new anthrax vaccine based on mutant forms of the bacterium's toxic proteins could be on the horizon.

Written byDavid Bruce
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00

The current anthrax vaccine has numerous side effects including headaches, fever and nausea and needs to be administered in regular booster doses to retain its protective ability. Rakesh Bhatnagar and colleagues at the Center for Biotechnology at the Jawaharlal Nehru University, New Delhi, India are to present three abstracts at the 41st Annual Meeting of the American Society of Cell Biology — on 11 December 2001 in Washington DC — revealing a potential vaccine for anthrax that doesn't have these side effects.

Bhatnagar begin looking for a suitable vaccine seven years ago following a major animal anthrax epidemic in West Bengal. The anthrax-causing bacterium, Bacillus anthracis, derives its toxicity from three proteins; protective antigen (PA), lethal factor (LF) and oedemal factor (OF). The proteins are harmless on their own but PA binds to LF to produce lethal toxin and to OF to form oedema toxin, which then affect the host. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Improving rAAV Production for Viral Vector Manufacturing

Improving rAAV Production for Viral Vector Manufacturing

cytiva logo
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Scientist holding a clear 384-well PCR microplate in a laboratory

What Dictates PCR Success Before Amplification Begins?

Integra Logo
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo